A5020932259- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- T-cell and B-cell Immunology
- CNS Lymphoma Diagnosis and Treatment
- Polyomavirus and related diseases
- Immune Cell Function and Interaction
- Histiocytic Disorders and Treatments
- Viral-associated cancers and disorders
- Renal Transplantation Outcomes and Treatments
- Chronic Myeloid Leukemia Treatments
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Women's cancer prevention and management
- SARS-CoV-2 and COVID-19 Research
- Lung Cancer Treatments and Mutations
- Eosinophilic Disorders and Syndromes
- Mesenchymal stem cell research
- Pneumocystis jirovecii pneumonia detection and treatment
- Hemoglobinopathies and Related Disorders
- Chronic Lymphocytic Leukemia Research
- Dermatological and COVID-19 studies
- Mast cells and histamine
- Xenotransplantation and immune response
- Cardiac Arrhythmias and Treatments
Universidade de São Paulo
2007-2025
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2017-2024
Hospital Sírio-Libanês
2018-2023
Hospital de Clínicas
2023
Délégation Paris 7
2022
Hôpital Saint-Louis
2020-2022
Université Paris Cité
2020-2022
Fred Hutch Cancer Center
2017-2021
D’Or Institute for Research and Education
2021
Instituto do Câncer do Estado de São Paulo
2020-2021
à la diffusion de documents scientifiques niveau recherche, publiés ou non, émanant des établissements d'enseignement et recherche français étrangers,
In the absence of prospective studies that examine effect conditioning regimen intensity after T-cell-replete haploidentical transplant for acute myeloid leukemia (AML), lymphoblastic (ALL), and myelodysplastic syndrome (MDS), a retrospective cohort analysis was performed. Of 1325 eligible patients (AML, n = 818; ALL, 286; MDS, 221), 526 received myeloablative 799 reduced-intensity regimen. Graft-versus-host disease prophylaxis uniform with posttransplant cyclophosphamide, calcineurin...
PURPOSE To compare the outcomes of patients with Hodgkin or non-Hodgkin lymphoma undergoing nonmyeloablative haploidentical unrelated cord blood (UCB) hematopoietic cell transplantation. PATIENTS AND METHODS We retrospectively studied 740 (n = 283, 38%) and 457, 62%) age 18-75 years who received transplantations from 2009 to 2016. Data were reported Lymphoma Working Party European Society for Blood Marrow Transplantation, Eurocord, Center International Transplant Research. Of 526...
ABSTRACT Immunocompromised individuals were considered high-risk for severe disease due to SARS COV-2 infection. This study aimed describe the safety of two doses COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan), followed by additional mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised (IC) adults, compared immunocompetent/healthy (H) individuals. phase 4, multicenter, open label included solid organ transplant and hematopoietic stem cell recipients, cancer patients...
Abstract Allogeneic hematopoietic cell transplantation (allo-HCT) is a highly complex, costly procedure for patients with oncologic, hematologic, genetic, and immunologic diseases. Demographics socioeconomic status as well donor availability type of health care system are important factors that influence access to outcomes following allo-HCT. The last decade has seen an increase in the numbers allo-HCTs teams all over world, no signs saturation. More than 80 000 procedures being performed...
Multiple myeloma (MM) associated with Chagas disease is rarely described. This and its therapy suppress T cell macrophage functions increase regulatory function, allowing the of parasitemia risk Disease Reactivation (CDR). We aimed to analyze role conventional (cPCR) quantitative Polymerase Chain Reaction (qPCR) for prospective monitoring T. cruzi parasitemia, searching markers preemptive antiparasitic in MM patients disease. Moreover, we investigated incidence management hematological...
We determined the incidence of disability related to chronic graft-versus-host disease (bronchiolitis obliterans, grade ≥2 keratoconjunctivitis sicca, sclerotic features or esophageal stricture) for three categories alternative donor: cord blood, haplorelated marrow peripheral blood with post-transplant cyclophosphamide, and unrelated single HLA-allele mismatched blood. Among 396 consecutive hematopoietic cell transplant recipients, 129 developed 3-year cumulative incidences 8% 24% grafts,...
In this prospective, randomized, phase II "pick the winner" trial we assessed efficacy of transplant conditioning with treosulfan/fludarabine ± 2 Gy total body irradiation (TBI) in reducing post-transplant relapse 100 patients, aged to 70 years (median, 57), myelodysplastic syndrome (MDS)/chronic myelomonocytic leukemia (n = 51) or acute myeloid (AML; n 49). Patients received i.v. treosulfan, 14 g/m2/day on days –6 –4 and fludarabine, 30 mg/m2/day –2, alone combined TBI (day 0). Donors were...
Although differences in the incidence of chronic graft-versus-host disease (GVHD) across races have been suggested, these not systematically investigated. This study compared incidence, sites, severity, and outcomes late acute GVHD according to National Institutes Health (NIH) consensus criteria between Japanese (n = 413) white 708) patients after first allogeneic hematopoietic cell transplantation. Analysis was stratified bone marrow transplantation (BMT) or peripheral blood stem (PBSCT)....
Abstract Double-unit unrelated cord blood transplantation (DUCBT) is an option in patients for whom a single unit not sufficient to provide adequate number of cells. As current guidelines on UCB selection are mainly based single-unit data, we performed retrospective analysis 1375 adult recipients DUCBT hematologic malignancies determine optimal criteria graft selection. Cryopreserved total nucleated cells (TNCs; ≤3.5 vs >3.5 × 107/kg: hazard ratio [HR], 1.53; 30% 45%; P = .01), HLA...
In single unrelated cord blood transplantation (UCBT), an increasing number of HLA allele mismatches (MM) has been associated with inferior overall survival (OS) and attributed to higher transplant-related mortality (TRM). Previous studies on the role allele-level matching after double UCBT (dUCBT) showed conflicting results. this study, we report impact outcomes a large dUCBT cohort. We included 963 adults hematologic malignancies, available at HLA-A, -B, -C, -DRB1, receiving between 2006...
Brentuximab vedotin (BV), an antibody drug conjugate against CD30, has been increasingly used in clinical practice, and the less common adverse events associated to are not well described. Also, opportunistic infections have reported, data on immune reconstitution after use of BV lacking. The authors describe a case 45-year-old man with Hodgkin lymphoma receiving as consolidation therapy autologous hematopoietic stem cell transplant. After nine months BV, patient developed respiratory...